Status:
COMPLETED
Neural Inhibition as a Mechanism of Nicotine Dependence Among Persons With Schizophrenia
Lead Sponsor:
Centre for Addiction and Mental Health
Collaborating Sponsors:
Canadian Psychiatric Research Foundation
Conditions:
Smoking
Nicotine Dependence
Eligibility:
All Genders
18-60 years
Phase:
NA
Brief Summary
Cigarette smoking decreases life expectancy, causes devastating health complications, and costs society billions of dollars each year. These untoward consequences are especially pronounced among perso...
Detailed Description
The prevalence of smoking is unusually high among patients with SCZ. In light of the negative health, economic, and social consequences of smoking, treatment efforts in this area are imperative. Such ...
Eligibility Criteria
Inclusion
- Voluntary and competent to consent
- Have a diagnosis of schizophrenia, schizophreniform, or schizoaffective disorder as confirmed by the Structured Clinical Interview for the DSM-IV (SCID-IV)
- Between the ages of 18 and 60
Exclusion
- Have a DSM-IV history of substance abuse or dependence (other than caffeine or nicotine) in the last 6 months
- Have a self-reported concomitant major medical or neurologic illness
- Pregnant
- Currently prescribed medications known to deleteriously affect cognition (e.g., benzodiazepines, tricyclic anti-depressants, anticholinergics, MAO inhibitors, GABA-B agonists)
- Currently taking clozapine (due to its documented effect on both NI and smoking
- Report suffering from conditions that may be aggravated by acute nicotine administration (e.g., arrhythmias, recent myocardial infarction)
Key Trial Info
Start Date :
February 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT00407277
Start Date
February 1 2007
Last Update
March 18 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre for Addiction and Mental Health
Toronto, Ontario, Canada, M5T 1R8